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Abstract
Background: Despite broad agreement on the necessity to improve quality of diabetic care
through implementation of clinical guidelines, in Italy many people with diabetes still lack adequate
care in general practice. In addition there is little evidence to support the choice of implementation
strategies, especially in the Lazio region (central Italy), where comparative studies among general
practitioners (GPs) are uncommon. The primary objective of the study is to assess the effectiveness
of different strategies for the implementation of an evidence-based guideline for the management
of non-complicated type 2 diabetes mellitus (DM) among GPs of the Lazio region.
Methods/Design:  Three-arm cluster-randomised trial (C-RCT). 252 GPs were randomised
either to arm 1 (comprising a training module and administration of the guideline), or to arm 2
(administration of guideline without training), or to arm 3 (control arm), continuing current
practice. Arm 1 participants attended a two-day course with CME credits. Data collection will be
performed using current information systems. Patients' health data was also collected to describe
diabetic populations cared for by GP participants. Process outcomes will be measured at the patient
level and at the cluster level one year after the intervention. We will assess GPs' adherence to
guideline recommendations for diabetes management relative to: 1) pharmacological management
of diabetes; 2) pharmacological management of cardiovascular risk factors (hypertension and
dislypidaemia); 3) measurement of glycosilated haemoglobin as the principal indicator of glycaemic
control; 4) micro- and macrovascular complications assessment tests. Outcomes will be expressed
as proportions of patients cared  for by GPs who will have prescriptions of drugs, requests for tests
and for outpatient appointment visits. To estimate the efficiency of resource use associated with
the intervention a cost-effectiveness analysis will be carried out. The design of the study is based
on three Cochrane and one Health Technology Assessment systematic reviews of guideline
dissemination and implementation strategies.
Background
In Italy diabetes mellitus (DM) is a major health problem
with a prevalence of 3–4% [1,2]. Considerable resources
are committed to addressing important clinical problems
connected with the treatment of micro- and macrovascu-
lar complications [3].
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In Italy, patients with type 2 non-complicated DM are
mainly treated in generale practice, whereas patients with
type 1 DM usually receive care from specialists.
Although clinical guidelines are available from traditional
means, data from an unpublished survey, conducted in a
local health district of Lazio, show that the overall quality
of DM care is generally poor and that the management of
DM often fails to achieve the established standards.
Outcome measures
The most efficacious guidelines implementation strategies
for changing general practitioner's (GP) behaviour are a
topic for debate. A systematic rewiew by Grimshaw et al
[4] concluded that there is an imperfect evidence base to
support decisions on which strategy is likely to be effi-
cient, due to methodological weakness of the majority of
the studies included in the review.
Further uncertainties concern knowledge on service
organisation and delivery of diabetic care and the lack of
comparative studies on the effects of guideline implemen-
tation strategies in Italy [4].
We report on the design of a cluster-randomised trial (C-
RCT) to assess the effects of two different strategies of
introducing evidence-based guidelines for the treatment
of type 2 DM in primary care. The C-RCT design (ran-
domisation at the level of professional practice or health
care organization) represents the optimal design when
evaluating dissemination and implementation strategies
[5].
As systematic reviews can inform and contribute to the
correct design of randomised controlled trials, our proto-
col is based on three Cochrane and one Health Technol-
ogy Assessment systematic reviews of guideline
dissemination and implementation strategies. All reviews
were prepared by members of the Cochrane EPOC group.
Objectives
The primary objective of the study is to assess the effective-
ness of different strategies for the implementation of an
evidence-based guideline for the management of non-
complicated type 2 DM among GPs of the Lazio region of
central Italy. Our null hypothesis is that a structured inter-
vention will be no more effective than a passive dissemi-
nation of the guideline or a no-intervention strategy.
The secondary objective is to estimate the efficiency of
resource use associated with the intervention through a
cost-effectiveness analysis.
The third objective is to try to generalise our trial's find-
ings to the rest of the GP population, mostly identifying
the existence, the tipology and the direction of barriers to
the implementation of the guideline in the primary care
setting of Lazio region.
Methods
The choice of diabetes guideline
As a first step, we conducted a systematic review of the
existing guidelines on diabetes care. Secondly, we used the
quality assessment criteria and the quality assurance
scores of the National Guideline Program of the Italian
Institute of Health [6].
Thirdly, we performed a qualitative assessment of guide-
lines applicability to our regional context.
We chose the following guideline: Stratégie de prise en
charge du patient diabétique de type 2 à l'exclusion de la
prise en charge des complications. ANAES(Agence
Nationale d'Accréditation et d'Evaluation en Santé) [7].
The guideline has been translated, updated and adapted
for Italian GPs.
Study design
We chose a three-arm C-RCT. Single GPs are the unit of
randomization and allocation is based on clusters.
Arm 1 includes GPs who underwent a two-day training
module and consequent administration of the guideline.
Arm 2 includes GPs who received the guideline without
any training but with a written request to implement the
guideline.
Arm 3 includes GPs who continue current practice (con-
trol group).
Data on the care process for DM are being collected during
the 12 months of duration of the study and main out-
comes on GPs' prescribing behaviour will be constructed.
Methodological basis
The study follows the methodological recommendations
and is based on the findings of systematic reviews per-
formed by the Cochrane EPOC Group [8-10].
Grimshaw et al's review reported poor methodological
quality of the majority of the included studies and, in par-
ticular, identified three recurring errors in C-RCTs:
Unit of analysis errors, when the unit of randomisation is
the GP but the unit of analysis is the patient analysed
independently of the cluster.BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/13
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Baseline imbalance, when small arm denominators may
cause imbalance between arms in important prognostic
factors (e.g. baseline performance).
Within groups comparisons, when investigators undertake
within groups analysis, rather than between groups.
Study setting and selection of participants
The study is carried out in the primary care setting of Ital-
ian National Health Service in the Lazio region. Eligible
study participants are GPs taking part in an electronically-
linked disease surveillance network and receiving a spe-
cific fee for computer-made prescriptions. Recruitment
was performed by an invitation letter written in a stand-
ardized format, giving information about the study
project. Five hundred GPs accepted to participate.
Sample size considerations
GPs were randomly selected from those who accepted to
participate and randomised. As the observations on indi-
viduals in the same cluster tend to be correlated, C-RCTs
require more participants than individually randomised
RCTs, to obtain equivalent statistical power. Therefore,
the sample size calculation took into account the estimate
of the average number of diabetic patients per GP and the
need to adjust for intracluster correlation factor, that, on
the basis of the unpublished survey, was estimated to be
0.1 [11].
To demonstrate a 10% difference in effect, with a power of
90% (1- beta = 0.90) and a statistical significance level of
5% in outcome measures between the control and inter-
vention groups, we estimated a need for a sample of 252
GPs [12]. Allocation was based on clusters. Random selec-
Flow diagram of the progress through the phases of the trial Figure 1
































Assessed for eligibility  
(n = 4744) 
Excluded (n = 4492) 
Not meeting inclusion criteria (n = 2596) 
Refused to partecipate  
(n = 1579) 
Accepted to partecipate but not sampled  
(n = 293) 
Not received invitation letter (n = 24 ) 
Randomised (n = 252) 
Allocated to intervention 1* (n = 84) 
Received intervention 1as allocated (No of clusters: 72; 
average cluster size: 24; range of clusters: 2-65) 
  1 withdrawal (reason: not transmitted patients’ 
data) 
Did not receive or partially received intervention 1 as 
allocated (No of clusters: 12; average cluster size: 21; 
range of clusters: 7-36) 
  3 not participated (reasons: health reasons, 
family reasons, personal commitments) 
  2 participated only to the first day training 
course (reasons: health reasons, family 
reasons, personal commitments) 
  7 participated only to the second day training 
course (reasons: health reasons, family) 
reasons, personal commitments) 
 
Allocated to intervention 2^ (n = 85) 
Received intervention 2 as allocated (No 
of clusters: 82; average cluster size: 26; 
range of clusters: 3-73) 
  1 lost to follow-up (unknown 
reasons) 
Did not receive intervention 2 as 
allocated (No of clusters: 3; average 
cluster size: 18; range of clusters: 3-33) 
  3 withdrawals (reasons: not 
satisfied with patients’ data 
protection system, time 
constraints and lack of interest) 
Allocated to control group °(n = 83) 
(No of clusters: 83; average cluster 

























*: Two-day training course + CME credits 
^: Passive dissemination of the guideline 
°: No intervention group, continuing current practice BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/13
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tion and randomization were performed by "REXSCO"
[13] software.
A flow-chart of participants' progress in the trial is at Fig-
ure 1.
Data collection
The main study outcome measures will be rates of per-
formance of process of care for diabetic patients identified
by recruited GPs. In this design, GPs are "units of meas-
ure" of the process of diabetic care delivery, as they man-
age laboratory and preventive care for most patients with
type 2 DM.
Individual patients' data were collected and two different
data sources were considered. Patient's anagraphic and
health status data (baseline information) were transmit-
ted through an on-line compilation. GP participants were
given a login and a password to access personal web
pages. The aim of collecting personal data is to describe
accurately the diabetic population on which physician's
behaviour may have an impact.
The second data set is based on drug prescriptions,
requests for tests and for outpatient appointment visits.
These data will be extracted by current information sys-
tems, which routinely assemble data for reimbursement
purposes. Thus, data from administrative databases may
be used to perform a cheap and exhaustive assessment of
GP's performance and of the effectiveness of methods for
influencing diabetes care process and outcome.
Similar baseline data (for the 12 months prior to the inter-
vention) will be collected for all outcomes.
Details of intervention
In our trial the intervention pertains to the GP (cluster)
level.
Although Grimshaw et al's systematic review has sug-
gested that different combinations of multi-faceted inter-
ventions appear to be more effective than single
interventions, we have decided to give priority to cheaper
and more feasible interventions compared to potentially
more effective, but more expensive and complex,
interventions.
Therefore, we structured the intervention through a proc-
ess of identifying barriers to implementation of recom-
mendations and factors that may facilitate changing
professional behaviour, together with an estimation of the
resources available within the governance budget. It is
often difficult to bring clinical practice in line with the sci-
entific evidence by "passively disseminating" guidelines
alone.
In brief, we developed the intervention in accordance with
the following criteria:
• to be preferably a single and not a multi-faceted
intervention
• to be easy to carry out
• to be reproducible in the implementation of other
guidelines
The main components of the intervention were:
• a two-day training course
• CME credits
The training course was organized as parallel sessions of
teaching modules together with interactive and group
work sessions with discussion of the content of the guide-
line. An entry questionnaire was given to participants to
obtain a picture of the current care provided to diabetic
patients.
Generalisability
An important issue of our C-RCT is the generalisability
(external validity) of the trial's findings at the cluster (GP)
level. The previous cited reviews [8-10] reported possible
not specific effects on the control arms of C-RCTs which
could hinder generalisability of results.
Commonly, Lazio region's GPs have difficulty in being
involved in institutional programs for improving the
quality of care. Numerous barriers can be identified.
"Internal" barriers include time constraints, possibly inad-
equate reimbursement and disagreement with innovative
programs. "External" barriers include individual patient
needs, limited systems to support chronic disease man-
agement and poor patient adherence to treatment. Fur-
thermore, a large part of GPs may not be accustomed to
web-based data loading. Finally, Lazio GPs may not be
accustomed to taking part in trials. On the basis of these
observations we hypothesize that the performance of the
control group (current practice arm) could be different
from "true" current practice, and that it could uncon-
sciously improve from the trial's beginning, with the con-
sequent underestimation of the effects. This may have an
impact on the applicability of the results on large scale.
Our intention is to test the presence and direction of aspe-
cific effects on arm 3, by means of a controlled before-
and-after (CBA) analysis. A CBA is made possible by our
use of routine data collection systems.BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/13
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Principles of data analysis
We will carry out comparisons between intervention and
control groups.
All analysis will be "intention to treat" and performed at
the individual level. Absolute risks (RA) and relative risks
(RR) with confidence intervals will be calculated. A
multivariate analysis will be performed to assess the role
of physician-associated factors (age, sex, median number
of patients and geographical area of the surgery). One
interim analysis at 6 months and one final analysis will be
carried out.
We will carry out a CBA analysis using cluster-adjusted
chi-square test [14].
Outcome measures
Policy makers need to have information about the likely
benefits and costs of different guideline dissemination
and implementation strategies, as they must make
informed decisions about the opportunity of introducing
guidelines in common practice. Nevertheless, as Grim-
shaw's review show (4) and other reviews report [15], the
methodological quality of economic evaluations of guide-
line dissemination and implementation strategies is gen-
erally poor and data reporting on costs and effects are
insufficient to be useful for decision-makers planning
guideline implementation in their own setting.
A cost-effectiveness analysis will be performed, from the
perspective of the policy decision maker and reported in
accordance with the BMJ criteria [16]. We will limit the
evaluation to the estimation and interpretation of mar-
ginal costs and benefits of changing practice. We will cal-
culate cost-effectiveness ratios (CER), measuring the
incremental costs of arms 1 and 2 compared to those in
the control arm.
Outcomes measures
Patient's health outcomes will be not registered. Process
of care variables are considered study outcomes, all aimed
at assessing physician-changing behaviour for the 12
months following the intervention. We will assess GPs'
adherence to guideline recommendations for DM man-
agement relatively to the following issues:
• pharmacological management of diabetes
• pharmacological management of cardiovascular risk fac-
tors (hypertension, dislypidaemia)
• measurement of glycosilated haemoglobin as the princi-
pal indicator of glycaemic control
• tests to assess possible micro- and macrovascular risks
and/or complications of DM
Outcomes will be expressed as proportions of patients
with drug prescriptions, requests for tests and for outpa-
tient appointment visits. For pharmacological indicators,
patients are considered as previously untreated if they
have no medication prescriptions recorded in the 12
months prior to the beginning of the trial.
We will also investigate the following areas:
• differences in health care resources consumption
• differences in comparing the costs of the study with the
benefits resulting by the intervention (see Economic eval-
uation paragraph)
A list of categories of the study outcomes, with the main
outcome of each category, is reported in table 1.
Table 1: List of outcome measures
Group 1 Group 2 Group 3 Group 4












Main outcome Proportion of patients who 
were prescribed 3 
measurements of 
glycosilated haemoglobin 
with at least two months' 
interval
Proportion of patients who 




Proportion of patients who 




Marginal cost per each 
glycosilated haemoglobin 
measurement
(1)ECG+lipid assessment (totalcholesterol + HDL cholesterol + triglycerides). (2) Ophtalmologic visit + funduscopy + urine albumin + serum 
creatinineBMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/13
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Presentation of results
Study results will be summarised in the following tables.
Table 1. Study participants' flow
Table 2. Before and after comparison of training course
test results
Table 3. Description of characteristics of GPs
Table 4. Baseline data of diabetic patients cared for by par-
ticipant GPs
Table 5. Glycaemic control evaluation outcomes
Table 6. Micro- and macrovascular complications assess-
ment tests
Table 7. Indicators of pharmacological management of
diabetes
Table 8. Indicators of pharmacological management of
cardiovascular risk factors
Table 9. Economic evaluation outcomes
Ethical aspects
The project is exempt from ethical clearance according to
the Italian Ministry of Health law number (ex art. 12bis,
Dlgs 229/1999). The Italian Data Protection act will be




The study is funded by the Italian Ministry of Health
("Special Programs" art. 12 bis D.lgs 229/99) and the
Lazio Region. Agency of Public Health of Lazio region
provided the computer instruments for data collection
and the resources for planning and organizational
support.
Note
The text of this protocol has been revised on the basis of
the recommendations of the CONSORT statement exten-
sion to C-RCTs [17].
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